logo

International Scholarly Research Notices

International Scholarly Research Notices / 2013 / Article / Tab 2

Clinical Study

Supplementation with High Doses of Vitamin D to Subjects without Vitamin D Deficiency May Have Negative Effects: Pooled Data from Four Intervention Trials in Tromsø

Table 2

Delta values ( , value at the end of study minus value at baseline) in the four separate studies and pooled together.
 Obesity studyInsulin sensitivity studyBone density studyDepression studyAll studies together
 Vitamin DPlaceboVitamin DPlaceboVitamin DPlaceboVitamin DPlaceboVitamin DPlacebo
All subjects ( )2211124945134139119109523405
BMI (kg/m2)0.0 (1.2)0.2 (1.4)−0.3 (0.9)−0.1 (1.0)−0.0 (1.0)−0.1 (2.1)0.1 (0.8)0.1 (0.8)0.0 (1.0)0.0 (1.5)
Serum 25(OH)D nmol/L49.3 (21.7)***−2.2 (9.5)100.5 (27.8)***3.7 (17.5)114.7 (34.5)***17.9 (18.8)100.2 (29.6)***4.7 (14.2)82.4 (40.1)***7.2 (17.3)
Serum calcium (mmol/L)−0.01 (0.12)−0.01 (0.11)−0.06 (0.08)−0.07 (0.09)0.02 (0.09)−0.01 (0.10)0.02 (0.08)*−0.01 (0.08)0.00 (0.10)*−0.01 (0.10)
Serum PTH (pmol/L)−0.86 (1.47)**−0.28 (1.58)−0.16 (1.42)*0.67 (1.90)−1.19 (1.38)***−0.62 (1.52)−0.78 (1.25)***0.19 (1.36)−0.86 (1.42)***−0.16 (1.60)
Subjects not on lipid medication ( )214105474211912311296492366
Serum TC (mmol/L)−0.12 (0.58)−0.19 (0.54)0.01 (0.58)−0.05 (0.64)0.18 (0.74)0.06 (0.78)−0.12 (0.53)−0.07 (0.70)−0.04 (0.62)−0.06 (0.68)
Serum TG (mmol/L)0.01 (0.89)0.07 (0.59)−0.04 (0.67)−0.02 (0.81)0.07 (0.58)0.02 (0.47)−0.16 (0.73)−0.11 (0.62)−0.02 (0.77)0.00 (0.59)
Serum HDL-C (mmol/L)−0.08 (0.17)−0.09 (0.18)0.02 (0.19)−0.01 (0.25)0.03 (0.25)−0.04 (0.27)0.03 (0.17)0.08 (0.19)−0.02 (0.20)−0.02 (0.23)
Serum LDL-C (mmol/L)−0.26 (0.51)−0.33 (0.48)0.07 (0.47)0.07 (0.54)−0.02 (0.59)−0.08 (0.66) −0.04 (0.47)−0.01 (0.61)−0.12 (0.53)−0.12 (0.60)
Serum Apo A1 (g/L)0.01 (0.17)0.00 (0.16)−0.03 (0.23)−0.03 (0.21)0.06 (0.17)0.04 (0.19)−0.09 (0.15)−0.06 (0.16)−0.01 (0.18)−0.01 (0.18)
Serum Apo B (g/L)−0.01 (0.13)−0.02 (0.13)−0.06 (0.10)−0.05 (0.12)0.01 (0.15)0.00 (0.15)−0.04 (0.11)−0.03 (0.13)−0.01 (0.13)−0.02 (0.14)
HbA1c (%)0.10 (0.22)0.07 (0.23)0.12 (0.32)0.05 (0.29)−0.11 (0.28)−0.12 (0.27)−0.03 (0.20)−0.01 (0.22)0.02* (0.26)−0.02 (0.26)
Serum HS-CRP (mg/L)0.11
(−0.60, 1.00)		−0.10
(−0.69, 0.88)		−0.04
(−0.54, 0.23)		−0.02
(−0.20, 0.49)		0.02
(−0.22, 0.43)		0.00
(−0.53, 0.31)		−0.06
(−0.41, 0.35)		−0.01
(−0.85, 0.39)		0.02
(−0.47, 0.59)		−0.03
(−0.55, 0.45)
, , and versus placebo group; general linear model adjusted for age, BMI, and gender. Data are shown as mean (SD) or median (25, 75 percentile). BMI: body mass index; 25(OH)D: 25-hydroxyvitamin D; PTH: parathyroid hormone; TC: total cholesterol; TG: triglycerides; HDL-C: HDL cholesterol; LDL-C: LDL cholesterol; Apo A1: apolipoprotein A1; Apo B: apolipoprotein B; HbA1c: glycated hemoglobin; HS-CRP: high sensitivity C-reactive protein.